izalontamab brengitecan

News

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.